



Powerwand™

Midline and Extended Dwell Catheters

icumedical
human connections

The Powerwand™

Infection Control:

Multiple independent studies demonstrated that use of Powerwand catheters, coupled with additional clinical measures, showed a reduction in occurrence of bloodstream infections.²⁻⁵

Cost Savings:

A retrospective analysis of a 5-year, 1,086 patient experience, delivering antibiotic administration through Powerwand, demonstrated that a hospital using Powerwand for antibiotic administration could potentially save more than \$95,000 per year.³

- > Shown to inhibit bacterial attachment (in vitro)²
- > Shown to reduce thrombus formation (in vivo)¹
- > Multiple independent studies demonstrated that use of Powerwand catheters, coupled with additional clinical measures, showed a reduction in occurrence of bloodstream infections.²⁻⁵
- > High power injection rating: 8 mL/sec, 325 psi

High Flow:

High flow rates: 75-185 mL/min

Echogenic:

Echogenic properties of the Powerwand™ catheter allow for ultrasound visualization once in the vein

Power Injection:

High power injection rating: 8 mL/sec, 325 psi

Kink Resistance:

The unique material, ChronoFlex C®, of the Powerwand™ catheter is designed to be kink resistant to provide reliability during both insertion and dwell times



Powerwand™ material




Standard catheter material

Thromboresistant:


The Powerwand™ catheter is shown in vivo to resist thrombus formation with respect to thrombus on the surface of the catheter and thrombus on the wall of the vein, as compared with a commonly used control device¹

Thermoformed Tip:


Catheter tip is thermoformed to avoid jagged edges




Powerwand™ Catheter



Trimmed Catheter



Control Device



Powerwand™ Catheter

1. FDA-cleared 510(k) Powerwand has shown in vivo to be thromboresistant with respect to both thrombus on the surface of the catheter and thrombus on the wall of the vein, based upon 72-hour canine jugular vein thromboresistance studies. This pre-clinical in vivo evaluation does not necessarily predict clinical performance with respect to thrombus formation.
2. Pathak R, Bierman SF, d'Arnaud P. Inhibition of bacterial attachment and biofilm formation by a novel intravenous catheter material using an in vitro percutaneous catheter insertion model. Med Devices (Auckl). 2018 Dec 19;11:427-432. doi: 10.2147/MDER.S183409. PMID: 30588133; PMCID: PMC6305250
3. Caparas JV, Hung HS. Vancomycin administration through a novel midline catheter: summary of a 5-year, 1086-patient experience in an urban community hospital. J Vasc Access. J Vasc Access 2017;22(1):38-41.
4. *DeVries M, Lee J, Hoffman L. Infection free midline catheter implementation at a community hospital (2 years). Am J Infect Control. 2019;47(9):1118-1121.
5. Pathak R, Patel A, Enuh H, et al. The incidence of central line-associated bacteremia after the introduction of midline catheters in a ventilator unit population. Infect Dis Clin Pract (Baltim Md). 2015;23(3):131-134.

* PowerGlide (CR Bard, Salt Lake City, UT) - a registered trademark of C.R. Bard. POWERWAND. ChronoFlex C is a registered trademark of AdvanSource Biomaterials Corp.
*M.D. and N.M. was a paid consultant for Access Scientific, LLC. Smiths Medical acquired the assets of Access Scientific, LLC on May 13, 2020.

Contact us today to find out how Powerwand can help enhance your infection control practices. Visit www.icumed.com/powerwand or call 866.488.6088

icumedical
human connections